30 Day Trial

Amend Surgical Receives Funding from Florida State


Amend Surgical entered into a funding agreement with The Florida Institute for the Commercialization of Public Research addressing newly-licensed technology developed at the University of Florida.

Amend Surgical received its first FDA 510(k) clearance in 1Q17 for NanoFUSE® BA as a bone graft extender for spine and orthopaedic applications. Its pipeline includes osteoinductive bone extracts and future disruptive products based on therapeutic additives, like antibiotics and natural bone morphogenic proteins.

The Florida Institute bridges early funding gaps for companies that license technology out of Florida-based universities and research institutions. Earlier this year, Amend entered into an exclusive agreement with The University of Florida Research Foundation to license patents for the development of Biomimetic Bone artificial bone substitute.

Sources: Florida Institute for the Commercialization of Public Research; ORTHOWORLD Inc.